Loading...

ACAD ACADIA PHARMACEUTICALS INC Company Mergers 8-K Filing

CD P

CD

ACADIA PHARMACEUTICALS INC

(ACAD)

2023 8-K

Show Summary

Show Summary

Management Changes

Earnings Releases

Bylaw Amendments

Financial Results

Management Change

Q3 Financial Results

Financial Results Announcement

Annual Meeting Approval

Financial Results Announcement

Results of Phase 3 ADVANCE-...

Financial Results Announcement

Departure of Directors

Management Change

Financial Results Announcement

Financial Results Announcement

Financial Results Announcement

Financial Results Announcement

External Links:

ACADIA Pharmaceuticals has entered into a joint venture and license agreement with Neuren Pharmaceuticals to commercialise and develop trofinetide and Neuren's development candidate NNZ-2591. ACADIA will make an initial upfront payment of $100 millio

AI Assistant

ACADIA PHARMACEUTICALS INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.